Eli Lilly’s EloraTZP, a combination of eloralintide and tirzepatide, has proven more efficacious than tirzepatide alone in a Phase IIb weight loss trial.
In the study (NCT06603571), those who received Lilly’s combination had average weight loss of 54.1lbs (23.3%) and A1C lowering by an average of 2.9% at 48 weeks. With each drug alone, patients who received eloralintide saw a reduced body weight of 28.6lbs (12.3%) and A1C of 1.4%, while tirzepatide 15mg reduced body weight by an average of 34.4 lbs (14.8%) and A1C by 2.4%.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The primary endpoint investigated EloraTZP against placebo that at the highest dose led to a 20.3% placebo-adjusted weight loss, equivalent to a 23.7lb. The placebo-adjusted A1C reduction was 2.6%.
EloraTZP was developed to simultaneously activate three complementary nutrient-stimulated hormones: GIP, GLP-1, and amylin, with minimal activity at the calcitonin receptor. These substances are released naturally by the body after eating, with each acting through its own distinct receptor to help regulate hunger and blood sugar.
The parallel-group, double-blind, placebo-controlled Phase IIb trial enrolled 367 adults with obesity or overweight and type 2 diabetes. Data was presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), which is taking place from 28 September to 2 October in Milan, Italy.
The results mark a strong data debut for EloraTZP, which appears to have also topped the weight loss seen from Lilly’s triple-G drug candidate retatrutide, though no head-to-head trial has been conducted.
Lilly is investigating eloralintide alone in several Phase III trials, dubbed the ENLIGHTEN programme, with all the studies pitting the selective amylin receptor agonist against placebo.
Everyone seeking entry to lucrative obesity market
The competition in the obesity and type 2 diabetes space is growing exponentially. The main companies in the space are Eli Lilly and Novo, who are fighting to be leaders in both the injectable and oral space.
Lilly is currently winning in the injectable space with tirzepatide, which is marketed as Mounjaro in type 2 diabetes and obesity in all countries but the US and Zepbound in obesity in the US, having generated more than $15bn in revenue for the pharma giant in Q2 2026.
In the oral weight loss space, Novo has gained a first-to-market advantage in the US, Europe and the UK for oral Wegovy, which are some of the key regions for these therapies.
Other major pharma companies are hoping to access the lucrative market, including Roche, Pfizer, AstraZeneca and Amgen.
GlobalData’s report, “GLP-1 Innovation Landscape 2026: Industry Insights,” reveals that the use of GLP-1RA drugs is rapidly expanding beyond treatments for diabetes and into mainstream weight management because they are effective at increasing satiety and reducing food intake, resulting in rapid weight loss.
Use among patients without diabetes but with overweight or obesity in the US rose 700% from 2019 to 2023, according to researchers from the University of Pennsylvania and Cedars-Sinai Medical Center.
While injectables remain the growth engine through 2031, the convenience and affordability of the GLP‑1RA pill format is expected to expand the user base, with pill market sales expected to rise from $3.2bn in 2025 to $34.3bn in 2031, according to GlobalData’s Pharmaceutical Intelligence Centre.
GlobalData is the parent company of Clinical Trials Arena.
